The Trump Administration in April 2026 announced a federal order directing agencies to speed up research and regulatory review of several psychedelic compounds, including ibogaine, a substance showing early promise in treating addiction, PTSD, and treatment-resistant depression.
The move is part of a broader shift in how the health agencies search for new mental health treatments and puts a spotlight on a compound most Americans have never heard of.
So, what is ibogaine and how does it compare to other psychedelic-related therapies such as ketamine?
What is ibogaine?
Ibogaine is a naturally occurring psychoactive compound, specifically, an indole alkaloid. It is derived from the root bark of the Tabernanthe iboga shrub, a plant native to the rainforests of West Central Africa.
It has been used for centuries in spiritual and initiation ceremonies by the Bwiti religious tradition, where the root bark is consumed in large doses as part of rites of passage.
Western medical interest in ibogaine traces back to 1962, when a young man reportedly took ibogaine recreationally and noticed his heroin withdrawal symptoms had disappeared.
That observation led to decades of scattered research into ibogaine as a potential treatment for opioid dependence. This research has only recently moved from the fringes into mainstream clinical trials.
Today, ibogaine occupies an unusual place in mental health research. It’s not a recreational drug in any meaningful sense. A full-dose ibogaine session is long, physically demanding, and most people describe it as profoundly serious rather than pleasurable.
Sessions typically last 12 to 36 hours, and patients often describe a dreamlike “waking REM” state. This can include vivid autobiographical visions involving review of past memories, relationships, and patterns of behavior, followed by a quieter reflective phase.
This experiential character, combined with its proposed effects on the brain’s underlying biology, is part of what has drawn researchers to study it as a potential treatment for some of the most difficult-to-treat mental health conditions.
How ibogaine works in the brain
Most psychiatric medications target one neurotransmitter system at a time. SSRIs, for example, work primarily on serotonin.
Ibogaine is unusual because it binds non-selectively to a wide range of receptors throughout the brain. This broad activity is part of why it’s interesting to researchers and part of why it has been challenging to study.
A few effects stand out as particularly important:
- Brain rewiring. Ibogaine appears to boost the brain’s ability to form new connections, a process called neuroplasticity. Researchers describe a “window” after treatment, possibly lasting weeks or even months, when the brain is more open to change. This window may give therapy and new habits a better chance to take hold.
- Support for dopamine neurons. Ibogaine increases a protein called GDNF in key parts of the brain. GDNF helps protect and grow the neurons that release dopamine, which plays a major role in motivation and reward. This effect is thought to help break the deeply ingrained brain patterns that drive addiction.
- Less withdrawal and craving. Early research suggests that a single ibogaine session can sharply reduce opioid withdrawal symptoms and drug cravings, sometimes for months at a time.
Once in the body, ibogaine breaks down into a longer-lasting compound called noribogaine, which is responsible for many of the longer-term effects researchers find promising.
Noribogaine appears to retain many of the same brain effects as ibogaine without producing the long psychedelic experience. Plus, it may carry less risk to the heart.
The first U.S. clinical trial of a noribogaine-based treatment began in April 2026.
What conditions is ibogaine being studied for?
Ibogaine is currently being investigated across several conditions where existing treatments often fall short. The proposed mechanism is somewhat different in each case, which is part of why the research is moving on multiple fronts.
Opioid use disorder
Opioid use disorder is the most studied application of ibogaine. The interest dates back to the original 1962 observation that ibogaine appeared to interrupt withdrawal symptoms. It has been the subject of observational studies and small clinical trials over the decades since.
Researchers think ibogaine works in a few overlapping ways. It appears to reset how the brain responds to opioids, quiet the cravings that drive drug use, and open a window of mental flexibility. This can create a state where people are more able to step back from compulsive patterns and see them clearly.
For a condition where most people relapse and current medications like methadone and buprenorphine require ongoing daily treatment, even a partial benefit from a single session would be a meaningful step forward.
Alcohol and other substance use disorders
Ibogaine and noribogaine are also being studied for alcohol, cocaine, and methamphetamine use disorders.
In April 2026, the US Food and Drug Administration (FDA) cleared a Phase 1 noribogaine trial for alcohol use disorder, the first of its kind. Researchers believe the effect of noribogaine is similar to its effect on opioid use: a mix of changes to dopamine signaling, increased brain flexibility, and a disruption of the habits that keep substance use going.
Post-traumatic stress disorder (PTSD)
Ibogaine’s potential role in PTSD treatment is one of the newer areas of research. It’s a major reason the compound has drawn federal attention, especially for veterans.
The way it may help is different from how it works in addiction. In PTSD, researchers think ibogaine’s effects on the brain’s fear-response system may allow people to revisit difficult memories without the same intense reaction.
The long, reflective nature of the ibogaine experience may also help people work through past events in a way that supports lasting relief.
Treatment-resistant depression
For depression that hasn’t responded to standard antidepressants, researchers are exploring ibogaine as a possible one-time or occasional treatment.
It is thought to work similarly to ketamine and psilocybin. A rapid boost in the brain’s flexibility may help loosen the rigid, negative thought patterns common in depression, while the following period of openness allows new perspectives to take hold.
Unlike daily antidepressants, ibogaine is being studied more as a periodic reset than an everyday medication.
Traumatic brain injury (TBI)
A 2024 Stanford University study followed veterans with traumatic brain injury who received ibogaine treatment outside the U.S. The study found significant reductions in PTSD, depression, and anxiety symptoms after a single session.
The results were striking enough to help drive the current federal interest in the compound. Researchers believe ibogaine may support recovery in injured brain tissue by encouraging the growth of new connections, though this area of research is still very early.
It’s important to keep in mind that across all of these conditions, the evidence is still early.
Most studies are small, often based on observation rather than controlled trials, and many took place outside the U.S. because of ibogaine’s legal status here. The new federal research push is designed to put these early findings through more rigorous testing.
How ibogaine compares to ketamine and other substances
For patients researching options for treatment-resistant depression, ketamine often comes up alongside ibogaine. Both are sometimes grouped under the “psychedelic medicine” umbrella, but they’re meaningfully different.
Ketamine and Spravato® (esketamine) work mainly by blocking a specific type of brain receptor called NMDA, which sets off a chain of changes that boost the brain’s flexibility. Researchers believe this is what causes its fast antidepressant effects.
Relief can come within hours to days, though the benefits usually last from days to a few weeks, which is why most people need repeated sessions.
Spravato is FDA-approved for treatment-resistant depression and major depression with suicidal thoughts, while ketamine is used off-label for a which range of conditions.
Ibogaine sessions look very different. They’re long and intense — typically 12 to 36 hours — and they require close medical monitoring because of the risk to the heart.
Its possible therapeutic effects are tied to a longer recovery window after treatment, sometimes lasting weeks to months. Ibogaine is not FDA-approved and isn’t available in regular medical care in the U.S. outside of research studies.
The bottom line: ketamine and Spravato are real, evidence-backed options for treatment-resistant depression that people can access today. Ibogaine is still an investigational treatment being studied for related but different uses, especially substance use disorders and trauma-related conditions.
Ibogaine isn’t the only psychedelic compound in active research. Trump’s executive order and the FDA’s follow-up actions also touched several others:
- Psilocybin (the active compound in psychedelic mushrooms) is being studied for major depressive disorder and treatment-resistant depression, with companies like Compass Pathways and the Usona Institute completing Phase 3 trials.
- MDMA-assisted therapy has been investigated for PTSD, though the FDA has raised concerns about study methodology in recent reviews and has not approved it for clinical use.
- Methylone, a compound related to MDMA, was granted a National Priority Voucher for further investigation in PTSD.
The shared thread across these compounds is a focus on conditions where existing treatments have not been enough, particularly treatment-resistant depression, PTSD, and substance use disorders.
Whether any of them ultimately becomes an approved treatment will depend on continued clinical research and FDA review.
What Trump’s executive order actually does
The executive order doesn’t make ibogaine legal or available for general use. Instead, it directs federal agencies to take several specific steps to accelerate the research pipeline.
The order calls on the FDA to issue Commissioner’s National Priority Vouchers to psychedelic drugs that have received a “breakthrough therapy” designation, which is a regulatory status given to investigational treatments that show early promise for serious conditions.
It directs the Department of Health and Human Services (HSS) to allocate at least $50 million to support state-level research programs.
It also instructs the Department of Veterans Affairs (VA) to collaborate with the FDA on clinical trial participation and data sharing. The focus on veterans in particularly important, as these individuals experience suicide rates more than twice that of the non-veteran adult population.
Safety concerns and why noribogaine is being prioritized
Ibogaine is currently classified as a Schedule I substance in the United States, meaning the federal government considers it to have no accepted medical use and a high potential for abuse. This classification has significantly limited research access for decades.
But beyond the legal status, there is a clinical reason ibogaine has not moved through the regulatory pipeline as quickly as other psychedelic compounds: cardiac risk.
Ibogaine can affect the heart’s electrical timing, specifically, how long it takes the heart to reset between beats. In rare cases, this can lead to a dangerous, irregular heartbeat. Most of the deaths linked to ibogaine have involved people with existing heart conditions, mixing it with other drugs, or taking it without medical supervision.
This is why the FDA has been cautious about ibogaine itself, and why the agency is putting more focus on related compounds like noribogaine, which may offer similar benefits with less risk to the heart.
What this means for patients today
The most important thing to know is that effective options already exist to treat a wide variety of mental health conditions. While the federal order may eventually expand the available treatment landscape, that process could take five to 10 years.
In the meantime, options like Spravato and ketamine therapy, transcranial magnetic stimulation (TMS), and medication management continue to offer real relief for people whose depression has been difficult to treat.
The right path forward depends on a careful conversation with a clinician who understands your full picture.
If you or someone you know is experiencing a mental health crisis, call or text 988. US military veterans can press 1 to be connected directly with the Veterans Crisis Line.
Frequently asked questions
What is ibogaine and where does it come from?
Ibogaine is a naturally occurring psychoactive compound derived from the root bark of the Tabernanthe iboga shrub, native to West Central Africa. It has been used for centuries in traditional Bwiti spiritual ceremonies and is now being studied as a potential treatment for substance use disorders, depression, PTSD, and traumatic brain injury.
What conditions is ibogaine being studied for?
Current research focuses on opioid and other substance use disorders, treatment-resistant depression, PTSD (particularly in veterans), and traumatic brain injury. The evidence base varies by condition and is most developed for substance use disorders.
Is ibogaine legal in the United States?
No. Ibogaine is currently classified as a Schedule I substance, meaning it is not approved for medical use in the U.S. Access is limited to authorized clinical trials. Some patients travel to countries where ibogaine treatment is legal, though this comes with significant safety considerations.
How is ibogaine different from ketamine and Spavato?
Ketamine and Spravato work primarily on the brain’s glutamate system to treat treatment-resistant depression and other conditions. Ibogaine works through multiple receptor systems, requires 12 to 36 hours of monitored treatment, and remains investigational in the U.S.
What did Trump’s April 2026 executive order do?
The executive order directed the FDA, HHS, and VA to accelerate research, regulatory review, and data sharing on psychedelic compounds with “breakthrough therapy” designation. It did not approve any new treatments or change ibogaine’s legal status.
What are the safety concerns with ibogaine?
The primary safety concern is cardiac risk. Ibogaine can affect the heart’s electrical timing, which in rare cases has led to dangerous arrhythmias. This is why the FDA is prioritizing the development of derivatives like noribogaine that may carry lower cardiac risk while preserving therapeutic effects.
Looking for mental health care services near you?
Pacific Mind Health offers medication management, therapy, and interventional treatments like transcranial magnetic stimulation (TMS) and ketamine and Spravato (esketamine).
Located in Southern California and serving patients across the state, Pacific Mind Health was founded by Joshua Flatow, MD, a board-certified psychiatrist and published peer-reviewed research author.
Ready to take the next step? Schedule a free consultation and start your mental health journey today.
